Tislelizumab (i.v. 200mg)

DRUG2 trials

Sponsors

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Oncomatryx Biopharma S.L.

Conditions

Colorectal CancerPancreatic Adenocarcinoma Metastatic

Phase 1

Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma

RecruitingNCT07377045

Oncomatryx Biopharma S.L.Pancreatic Adenocarcinoma Metastatic

Start: 2025-10-28End: 2029-03-01Target: 69Updated: 2026-01-29

Phase 2

Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities

RecruitingNCT06722183

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestColorectal Cancer

Start: 2025-12-16End: 2028-03-31Target: 33Updated: 2025-12-24